• 제목/요약/키워드: EAAT

검색결과 5건 처리시간 0.016초

소아청소년을 대상으로 한 재활승마 선별도구 : 델파이 방법을 통한 융합연구 (The Screening Tool for Equine Assisted Activities and Therapies in Children and Adolescents : A Convergence Study with the Delphi Method)

  • 황영섭;장현정;홍보영;이지영;권정이
    • 한국융합학회논문지
    • /
    • 제9권5호
    • /
    • pp.203-218
    • /
    • 2018
  • 본 연구의 목적은 국내 소아청소년을 대상으로 한 재활승마 선별도구를 개발하는 것으로, 승마장에서 재활승마지도사들이 참가자를 직접 선별 가능하도록 하기 위함이다. 예비 선별도구는 6명의 전문가가 기존 국외의 지침서들을 참조하여 개발하였으며 해당 인원이 포함된 총 23명의 전문가들을 대상으로 두 차례의 델파이 연구를 진행하였다. 선별도구 각 항목의 적절성에 대한 의견을 0점(비동의)~10점(동의)으로 총 11점 척도로 표시하도록 하였다. 항목의 적절성이 8점 이상인 경우를 합의된 항목으로 간주하였으며 8점 이상인 항목은 48개의 항목 중 39개의 항목이었다. 39 항목의 켄달의 일치계수에서 유의미한 결과값이 나타나(p<.001) 평가자간 의견일치가 되었음을 확인하였으며 따라서 최종 선별도구는 총 39개의 항목으로 구성되었다. 재활승마 선별도구는 참가자에게 보다 더 안전한 재활승마를 제공할 것이며 향후 성인을 대상으로 한 추가적인 연구가 필요할 것으로 보인다.

4-F-PCP, a Novel PCP Analog Ameliorates the Depressive-Like Behavior of Chronic Social Defeat Stress Mice via NMDA Receptor Antagonism

  • Darlene Mae D., Ortiz;Mikyung, Kim;Hyun Jun, Lee;Chrislean Jun, Botanas;Raly James Perez, Custodio;Leandro, Val Sayson;Nicole, Bon Campomayor;Chaeyeon, Lee;Yong Sup, Lee;Jae Hoon, Cheong;Hee Jin, Kim
    • Biomolecules & Therapeutics
    • /
    • 제31권2호
    • /
    • pp.227-239
    • /
    • 2023
  • Major depressive disorder is a leading cause of disability in more than 280 million people worldwide. Monoamine-based antidepressants are currently used to treat depression, but delays in treatment effects and lack of responses are major reasons for the need to develop faster and more efficient antidepressants. Studies show that ketamine (KET), a PCP analog, produces antidepressant effects within a few hours of administration that lasts up to a week. However, the use of KET has raised concerns about side effects, as well as the risk of abuse. 4 -F-PCP analog is a novel PCP analog that is also an NMDA receptor antagonist, structurally similar to KET, and might potentially elicit similar antidepressant effects, however, there has been no study on this subject yet. Herein, we investigate whether 4-F-PCP displays antidepressant effects and explored their potential therapeutic mechanisms. 4-F-PCP at 3 and 10 mg/kg doses showed antidepressant-like effects and repeated treatments maintained its effects. Furthermore, treatment with 4-F-PCP rescued the decreased expression of proteins most likely involved in depression and synaptic plasticity. Changes in the excitatory amino acid transporters (EAAT2, EAAT3, EAAT4) were also seen following drug treatment. Lastly, we assessed the possible side effects of 4-F-PCP after long-term treatment (up to 21 days). Results show that 4-F-PCP at 3 mg/kg dose did not alter the cognitive function of mice. Overall, current findings provide significant implications for future research not only with PCP analogs but also on the next generation of different types of antidepressants.

Study on Intracellular Zinc Uptake According to Zinc-ligand

  • Shim, Boo-Im;Kim, Ki-Nam;Kim, Yu-Ri;Lee, Seung-Ho;Lee, Seung-Min;Park, Myung-Gyu;Kim, Meyoung-Kon
    • Molecular & Cellular Toxicology
    • /
    • 제3권4호
    • /
    • pp.292-298
    • /
    • 2007
  • Zinc plays indispensable roles in metabolism, including cell growth, apoptosis, proliferation and differentiation. Kidneys are target organs for various regulators of mineral metabolism, and play a key role in zinc balance. To investigate the zinc uptake efficiency, we examined the zinc uptake and accumulation level in vivo and in vitro study. Plasma zinc concentration was peaked out at 1 hr after oral zinc administration. The renal zinc level was peaked out at 12 hr after oral zinc administration, and it was the highest in 40 mg/kg Zn-Asp administrated group in comparison with other groups. In addition, the m-RNA expression level of zinc transporter-1 (ZnT-1), zinc transporter-2 (ZnT-2) and high-affinity L-aspartate transporter (EAAT-3) in Zn-Asp administered group were increased compared with control groups and $ZnSO_4$ group. In order to investigate the intracellular zinc uptake mechanism, we performed the in vitro study by using human embryonic kidney cell line, HEK 293. Intracellular zinc level was peaked out at 3 hr after zinc treatment. In the same way, the mRNA expression level of ZnT-1 and EAAT-3 were increased compared with control group. This study showed that Zn-Asp is effective the zinc uptake into the kidney by increasing the zinc transporter expression.

Mass Spectrometry-Based Screening Platform Reveals Orco Interactome in Drosophila melanogaster

  • Yu, Kate E.;Kim, Do-Hyoung;Kim, Yong-In;Jones, Walton D.;Lee, J. Eugene
    • Molecules and Cells
    • /
    • 제41권2호
    • /
    • pp.150-159
    • /
    • 2018
  • Animals use their odorant receptors to receive chemical information from the environment. Insect odorant receptors differ from the G protein-coupled odorant receptors in vertebrates and nematodes, and very little is known about their protein-protein interactions. Here, we introduce a mass spectrometric platform designed for the large-scale analysis of insect odorant receptor protein-protein interactions. Using this platform, we obtained the first Orco interactome from Drosophila melanogaster. From a total of 1,186 identified proteins, we narrowed the interaction candidates to 226, of which only two-thirds have been named. These candidates include the known olfactory proteins Or92a and Obp51a. Around 90% of the proteins having published names likely function inside the cell, and nearly half of these intracellular proteins are associated with the endomembrane system. In a basic loss-of-function electrophysiological screen, we found that the disruption of eight (i.e., Rab5, CG32795, Mpcp, Tom70, Vir-1, CG30427, Eaat1, and CG2781) of 28 randomly selected candidates affects olfactory responses in vivo. Thus, because this Orco interactome includes physiologically meaningful candidates, we anticipate that our platform will help guide further research on the molecular mechanisms of the insect odorant receptor family.

Astrogliosis Is a Possible Player in Preventing Delayed Neuronal Death

  • Jeong, Hey-Kyeong;Ji, Kyung-Min;Min, Kyoung-Jin;Choi, Insup;Choi, Dong-Joo;Jou, Ilo;Joe, Eun-Hye
    • Molecules and Cells
    • /
    • 제37권4호
    • /
    • pp.345-355
    • /
    • 2014
  • Mitigating secondary delayed neuronal injury has been a therapeutic strategy for minimizing neurological symptoms after several types of brain injury. Interestingly, secondary neuronal loss appeared to be closely related to functional loss and/or death of astrocytes. In the brain damage induced by agonists of two glutamate receptors, N-ethyl-D-aspartic acid (NMDA) and kainic acid (KA), NMDA induced neuronal death within 3 h, but did not increase further thereafter. However, in the KA-injected brain, neuronal death was not obviously detectable even at injection sites at 3 h, but extensively increased to encompass the entire hemisphere at 7 days. Brain inflammation, a possible cause of secondary neuronal damage, showed little differences between the two models. Importantly, however, astrocyte behavior was completely different. In the NMDA-injected cortex, the loss of glial fibrillary acidic protein-expressing ($GFAP^+$) astrocytes was confined to the injection site until 7 days after the injection, and astrocytes around the damage sites showed extensive gliosis and appeared to isolate the damage sites. In contrast, in the KA-injected brain, $GFAP^+$ astrocytes, like neurons, slowly, but progressively, disappeared across the entire hemisphere. Other markers of astrocytes, including $S100{\beta}$, glutamate transporter EAAT2, the potassium channel Kir4.1 and glutamine synthase, showed patterns similar to that of GFAP in both NMDA- and KA-injected cortexes. More importantly, astrocyte disappearance and/or functional loss preceded neuronal death in the KA-injected brain. Taken together, these results suggest that loss of astrocyte support to neurons may be a critical cause of delayed neuronal death in the injured brain.